rghs_10k-093011.htm

1. Nature of Operations, Description of Business and Basis of Presentation

Nature of Operations

On May 28, 2010, Robertson Global Health Solutions Corporation (“RGHS”) (formerly ASI Technology Corporation (“ASI”)) completed the acquisition of NxOpinion, LLC and its subsidiary (“NxOpinion”), previously a privately-owned health care technology licensing company headquartered in Saginaw, Michigan (the “Merger”) pursuant to the terms of an Agreement and Plan of Recapitalization dated May 28, 2010 (the “Recapitalization Agreement”). As a result of the Merger, the business of NxOpinion is now owned by Robertson Health Services, Inc. (“RHS”), a wholly-owned subsidiary of the Company. The post-merger company is referred to herein as the “Company”, “we”, “us” or “our”.

The Company experienced a change in control, and therefore NxOpinion was deemed to be the acquiring company and for accounting purposes the Merger was considered to be a reverse acquisition and recapitalization.

Description of Business

The Company has developed RHealth Advisor, a medical knowledge platform powering a suite of health applications, including its leading diagnostic application, for global healthcare delivery. The core medical knowledge management system, use of mathematical and statistical bases and business process for the software was invented by NxOpinion’s founder and the Company’s CEO, Dr. Joel Robertson (“Dr. Robertson”) in 2002. The software uses rich web services allowing the use of mobile technology, personal computer and web interfaces to deliver a powerful suite of healthcare applications. RHealth Advisor’s medical knowledge applications include electronic health records, health tips, reference guide and diagnostic pre-screening that determines the probability of what condition may be afflicting a patient. In addition, RHealth Advisor provides the latest treatment options and referral to the appropriate level of care given presenting symptoms based on patient facts, health history, user skill level, geographical location, resources available and other available data. RHealth Advisor’s innovative design and flexibility allows for rapid customization for varied users, including healthcare workers, consumers, nurses, physicians and other health care providers, as well as tailoring for different countries, regions and languages. Recent pilot and development collaborations and discussions with healthcare technology leaders have demonstrated, in management’s view, that RHealth Advisor is ready for scaling for commercialization. The Company believes RHealth Advisor is a very powerful medical knowledge platform uniquely capable of being implemented in a wide range of settings worldwide, from rural health systems to the most sophisticated urban hospital systems.

Development Stage Enterprise

The Company follows the presentation and disclosure requirements of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915, Accounting and Reporting by Development Stage Enterprises. Although some principal operations of marketing and licensing software solutions commenced in 2009, the Company has not yet generated significant revenue and is still considered in the development stage.

Basis of Presentation

The financial statements have been prepared on the accrual basis by management in accordance with generally accepted accounting principles in the United States (“GAAP”) on a going concern basis, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. From inception to September 30, 2011, the Company has incurred significant losses and negative cash flow from operations and has a deficit accumulated during the development stage of $16,876,147. The Company's ability to emerge from the development stage and continue as a going concern is in doubt and is dependent upon obtaining additional financing and/or attaining a profitable level of operations. Management has plans to generate revenue producing business and to seek additional capital. These financial statements do not give effect to any adjustments that would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying financial statements.

F-6

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

Principles of Consolidation

In the consolidated financial statements and the notes thereto, all references to historical information, balances and results of operations are related to NxOpinion (now RHS) and its subsidiary as the predecessor company pursuant to reverse acquisition accounting rules. Under reverse acquisition accounting rules, the merged Company’s consolidated financial statements reflect NxOpinion’s results as a development stage company from NxOpinion’s inception on April 11, 2005. The Company’s operating results (post-Merger) include the operating results of NxOpinion and its subsidiary prior to the date of the Merger and the results of the combined entities following the closing of the Merger.

The consolidated financial statements include the accounts of RGHS (formerly ASI) and its wholly-owned subsidiaries. Subsidiaries of RGHS are Robertson Health Services, Inc. (RHS, comprising the former business of NxOpinion), Robertson Technologies Licensing, LLC (“RTL”, a wholly-owned limited liability company owned by RHS), ASI Capital Corporation (“ASI Capital”, a wholly-owned subsidiary that operates certain leased property) and ASI Land Holdings, Inc. (“ASI Land”, a wholly-owned subsidiary which previously held certain real estate). All significant intercompany balances and transactions have been eliminated. Certain amounts previously reported have been reclassified to conform to the current presentation.

Adjustments to Historical Financial Statements

The historical consolidated financial statements reflect the impact of the change in capital structure that resulted from the Merger as if that capital structure was in place as of April 11, 2005 (date of inception) and for all subsequent periods presented. Accordingly, the accompanying consolidated balance sheets as of September 30, 2011 and 2010, and the accompanying consolidated statements of stockholders’ deficit for the period from April 11, 2005 (date of inception) to September 30, 2011 have been adjusted to reflect the current capital structure of the Company. In financial statements published prior to the Merger, references to the previous capital structure were to members’ capital rather than stockholders’ deficit.

Fiscal Period

After the Merger, the Company’s Board of Directors approved a resolution to change the Company’s fiscal year end to September 30.

Use of Estimates in the Preparation of Consolidated Financial Statements

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period.

The Company regularly evaluates its accounting policies and estimates. In general, estimates are based on historical experience and on assumptions believed to be reasonable given the Company’s operating environment. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Actual results may differ from these estimates.

2. Summary of Significant Accounting Principles

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

Revenue Recognition

The Company recognizes revenue when there is evidence of an arrangement, the service has been provided to the customer, the collection of the fees is reasonably assured, and the amount of fees to be paid by the customer are fixed or determinable. To date, revenues have not been significant and the Company expects to enter into new software licensing and collaborative arrangements in the future and will evaluate each in accordance with Staff Accounting Bulletin 104 and the ASC’s Software and Collaborative Topics.

The Company’s business model includes collaborative arrangements resulting in the licensing of its software applications and related content with on-going license fees based on usage, availability or from advertising and sponsorships. Fees based on availability are recognized over the performance period; fees based on usage or from advertising and sponsorships are recognized as reported to the Company from intermediaries over the applicable period and when collection is assured.

F-7

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

The Company recognizes fees for contract services when the fees are fixed and determinable, the related services are performed and collection is assured. The Company evaluates revenue from arrangements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting as defined in the accounting guidance related to revenue arrangements with multiple deliverables.

Deferred revenue, including advance license fees, which will be recognized during the succeeding 12-month period, is recorded as current deferred revenue and any remaining portion is recorded as long-term deferred revenue.

Collaborative Arrangements

Contractual arrangements fall within the scope of ASC 808-10, Collaborative Arrangements, if the arrangement requires the parties to be active participants and the arrangement exposes the parties to significant risks and rewards that are tied to the commercial success of the endeavor. Collaborative agreement revenues may include both contract research revenue and license revenue. Nonrefundable up-front license fees where the Company has continuing involvement through research and development collaboration are initially deferred and recognized as collaborative agreement license revenue over the estimated period for which the Company continues to have a performance obligation. Nonrefundable amounts received for shared development costs are recognized as contract revenue in the period in which the related expenses are incurred.

Fair Value of Financial Instruments

The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value. Hierarchical levels are as follows:

Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar instruments in active markets, and inputs other than quoted prices that are observable for the asset or liability.

Level 3: Inputs are unobservable for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

The fair values of cash, other current assets and current liabilities approximate their carrying value due to the short-term nature of these financial instruments. See Note 14 for information on applying fair value measurements to other assets and liabilities.

Property and Equipment

Fixed assets are stated at cost. Depreciation and amortization are computed on the straight-line method over the estimated useful lives of the related assets. The depreciable life of leasehold improvements is the shorter of the lease term or the useful life. Upon asset retirement or other disposition, cost and the related accumulated depreciation are removed from the accounts, and any gain or loss is included in the consolidated statements of operations. Amounts expended for repairs and maintenance are expensed as incurred.

Software Product and Content Development Costs

Software product and content development expenditures include costs incurred in the development, enhancement and maintenance of software technology and content. These costs are charged to expense as incurred. Production costs after technological feasibility are not expected to be material and other computer software and content maintenance costs related to software and content development are expensed as incurred.

Real Estate

Real estate previously owned and held for sale included properties acquired through deed in lieu of foreclosure in December 2009. These properties were recorded at the lower of cost or estimated fair value with gain or loss recorded as recovery or additional loan loss. To assist estimating the fair value of these properties based on Level 3 inputs of ASC 820, Fair Value Measurements and Disclosure, management used current and prior appraisals, comparable local sales data, and where applicable adjustments to reflect the highest and best use of each parcel. Subject to periodic impairment considerations, the Company’s policy was to capitalize costs relating to any improvements of properties. Holding costs were charged to expense as incurred. Real estate owned was classified as held for sale in June 2010 when management determined it met the appropriate criteria in ASC 360-10-45. Real estate assets that are expected to be disposed of are valued on an individual asset basis at their carrying amounts, after any impairment adjustments necessary, less estimated costs to sell. All real estate holdings were disposed of in an installment sale with the final payment received in January 2011 (Note 5).

F-8

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

Facility Exit Liability

The Company accounts for an unused operating office lease in accordance with ASC 420, Exit or Disposal Cost Obligations, and is required to make continuing estimates related to estimated sublease and concession amounts.

Warrants Classified as Derivatives

The valuation of warrant derivatives resulted from insufficient member interests being available for exercise of the warrants prior to the Merger and was determined in accordance with ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity. The warrant fair value was adjusted each reporting period based on current assumptions, with the change in value recognized in other income (expense). Changes in remaining term, stock prices, stock volatility and interest rates changed the warrant liability each period resulting in a non-cash charge. The warrant liability was converted to equity upon the Merger (Note 3).

The Company reviews the classification of its warrants and other financial instruments as derivatives each period.

Stock-Based Compensation

The Company accounts for stock-based compensation under the provisions of ASC 718, Share-Based Payment, and ASC 505-50, Equity-Based Payments to Non-Employees. ASC 718 requires measurement of all employee stock-based awards using a fair-value method and recording of related compensation expense in the financial statements over the requisite service period. Further, as required under ASC 718, the Company estimates forfeitures for stock-based awards that are not expected to vest. Under ASC 505-50, options or stock awards issued to non-employees who are not directors of the Company are recorded at the estimated fair value of the stock options issued at the measurement date. Non-employee options are periodically revalued as the options vest so the cost ultimately recognized is equivalent to the fair value on the date performance is complete with such expense recognized over the related service period on a graded vesting method.

The Company accounts for the fair value of each option grant by estimating on the date of grant using the Black-Scholes option-pricing model including assumptions pertaining to expected life, interest rate, volatility and dividend yield. Expected volatilities are based on historical volatility of a peer group until the Company has sufficient history. The expected life of options granted represents an estimate of the period of time that options are expected to be outstanding, which is shorter than the term of the option. In addition, the Company is required to calculate estimated forfeiture rates on an ongoing basis that impact the amount of share-based compensation costs it will record. If the estimates used to calculate the fair value for employee stock options differ from actual results, or actual forfeitures differ from estimated forfeitures, the Company may be required to record gains or losses that could be material.

Loss Per Share

Loss per share is calculated by dividing net loss by the weighted average number of shares of the Company’s common stock outstanding during the period. At September 30, 2011 and 2010, a total of 1,786,617 and 1,452,119, respectively, of potentially dilutive securities consisting of options and warrants were not used for any computation of dilution for each period then ended as they would have been antidilutive.

Income Taxes

The Company accounts for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company provides a full valuation reserve related to its net deferred tax assets. In the future, if sufficient evidence of an ability to generate sufficient future taxable income in certain tax jurisdictions becomes apparent, the Company may be required to reduce the valuation allowances, resulting in income tax benefits in the consolidated statement of operations. The Company evaluates the realizability of the deferred tax assets and assesses the need for valuation allowance quarterly. The utilization of the net operating loss carryforwards could be substantially limited due to restrictions imposed under federal and state laws upon a change in ownership in the future. The Company has experienced various ownership changes as a result of past financings and could experience future ownership changes.

F-9

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

Recent Accounting Pronouncements

A number of new authoritative accounting standards have been issued during recent months that have been evaluated by the Company and determined not to have a material effect on the financial position and results of operations of the Company. Those recent accounting standards that could potentially have an impact if or when adopted are listed and discussed below:

In May 2011, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2011-04, Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS. This update explains how to measure fair value, does not require additional fair value measurements, and is not intended to establish valuation standards or affect valuation practices outside of financial reporting. This update results in common fair value measurement and disclosure requirements in U.S. GAAP and IFRSs. Consequently, the amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. The amendments in this Update are effective on a prospective basis for interim and annual periods beginning after December 15, 2011. The Company does not expect the adoption to have a material impact on its financial results.

In June 2011, the FASB issued authoritative guidance regarding comprehensive income. This newly issued accounting standard (1) eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity; (2) requires the consecutive presentation of the statement of net income and other comprehensive income; and (3) requires an entity to present reclassification adjustments on the face of the financial statements from other comprehensive income to net income. The amendments do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income nor do the amendments affect how earnings per share is calculated or presented. This guidance is required to be applied retrospectively and is effective for fiscal years and interim periods beginning after December 15, 2011. The adoption of this standard is not expected to have an impact on the Company’s financial position or results of operations.

3. Merger and Recapitalization

On May 28, 2010, RGHS completed the acquisition of NxOpinion, previously a privately-owned health care technology licensing company headquartered in Saginaw, Michigan. As a result of the Merger, the business of NxOpinion is now owned by RHS, a wholly-owned subsidiary of the Company.

Each NxOpinion security holder received, in exchange for each NxOpinion membership unit held or deemed to be held by such security holder immediately before the closing of the Merger, a number of shares of Company common stock equal to fifteen shares prior to the reverse split. The Company completed on August 6, 2010 a 1 for 15 reverse split and accordingly, as a result, each NxOpinion unit holder effectively received post-split one share of the Company for each unit of NxOpinion and each legacy shareholder of RGHS prior to the Merger received one post-Merger and post reverse split share for each 15 shares owned prior to the Merger. All share numbers herein reflect the Merger and the reverse stock split.

The Company has 20,000,000 shares of common stock, par value $0.001 authorized and 1,000,000 shares of preferred stock, par value $0.001, authorized. No preferred shares are outstanding. Just prior to the Merger’s effective date, stockholders of RGHS owned 1,154,248 shares of common stock. The former members of NxOpinion received 10,000,000 shares of the Company’s common stock in the Merger. The Company also issued at closing 214,223 shares at $1.00 per share to retire certain convertible note obligations of NxOpinion.

In connection with the Merger, the Company agreed to assume the debt and equity obligations of NxOpinion including convertible notes and warrants to purchase units of membership interest in NxOpinion that were converted into $170,000 of 11% convertible notes with principal and interest convertible at $1.00 per common share and warrants exercisable into 541,000 shares of the Company’s common stock at $1.00 per share and 170,000 shares at $2.50 per share.

F-10

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

Additional debt was restructured including:

At closing approximately $1.3 million was owed by NxOpinion to affiliated non-profit Robertson Research Institute (“RRI”), a Colorado nonprofit corporation, and a public charity as defined in section 501(c)(3) of the Internal Revenue Code. This amount was reduced by $900,000 at closing through debt forgiveness by RRI and treated as a capital contribution net of the value of warrants and a tax bonus (Note 6).

Secured notes outstanding with five parties with a principal balance of $357,500 (plus accrued and unpaid interest), effectively demand notes, were exchanged for new unsecured notes at the same interest rates. The holders were also issued warrants for shares of common stock of the Company on an aggregate basis for 21,450 common shares exercisable at $2.50 per share for three years.

Past consulting fees owed to two management advisors for $243,175 were exchanged for notes with a 5% annual rate of interest. The holders were also issued warrants on an aggregate of 14,591 common shares of Company stock exercisable at $2.50 per share for three years.

An obligation related to a $250,000 bank line of credit was assumed by the Company with Dr. Robertson continuing to guarantee the note. Dr. Robertson was issued warrants on an aggregate of 15,000 common shares of Company stock exercisable at $2.50 per share for three years as consideration for his continuing guarantee. In June 2010, this bank line was converted into a five year term note (Note 8).

At closing the Company was obligated on an unsecured installment payment agreement to NxOpinion’s legal firm with regard to outstanding legal fees owed for services incurred through May 28, 2010, with a total outstanding balance of $331,547 at an interest rate of 5% per annum compounded monthly. In November 2011, the Company negotiated revised terms on this loan. The note is due on demand, but not later than June 1, 2012, including interest at 5% per annum. Payments are to be made as excess cash flow permits after covering only ordinary operating expenses. The note is secured by the Company assets.

Subsequent to the Merger on June 3, 2010 the Company repaid $75,000 of NxOpinion 11% unsecured bridge notes.

Prior to, but in connection with, the Merger, RGHS disposed of the following assets and issued common stock on option exercises to pay closing and other operating costs and to provide working capital for the operations of the Company:

RGHS sold its direct financing lease interests with a book value of approximately $330,800 for cash of $280,000. Three directors and/or officers of RGHS, or entities controlled by them, purchased $150,000 of these interests on the same terms as negotiated at “arms’ length” with unaffiliated parties. These direct financing lease interests related to the financing and operation of 28 automated teller machines at various locations.

RGHS sold its marketable securities consisting of 246,502 restricted shares of common stock of e.Digital Corporation for $20,000 to an unaffiliated buyer. These securities were valued each reporting period at market price. The market price for unrestricted shares at the date of sale was $24,650.

The Company assigned its exclusive license agreement with the inventor of U.S. Patent #6,232,723 related to certain sterilization and decontamination technology in exchange for $5,500 of debt reduction to an unaffiliated party.

Stock option holders exercised 14,667 “out-of-the-money” stock options at exercise prices ranging from $3.00 to $6.75 per share for cash of $29,000 and debt reduction of $23,500. Two directors and one officer of RGHS exercised an aggregate of 8,000 of these options for proceeds of $25,000.

Additionally, with the prior agreement of NxOpinion and the Company, a company controlled by a former director, following the closing of the Merger, agreed to purchase for $300,000 on an installment basis certain intangible water rights held by the Company with a book value of $381,000.

The Company retained cash, after the asset sales described above, of approximately $250,000. RGHS also had certain liabilities, including an office facility exit liability of $74,068, at closing of the Merger. The Company retained certain assets owned prior to the Merger, including undeveloped real estate assets held for investment, which was later sold (see Note 5).

RGHS’s assets and liabilities as of May 28, 2010, the date of the Merger closing, have been incorporated into the Company’s balance sheet based on the fair values of the net assets acquired at that date, which equaled the consideration paid for the acquisition. Further, the Company’s operating results (post-Merger) include NxOpinion’s operating results prior to the date of closing and the results of the combined entity following the closing of the Merger. Although NxOpinion (now RHS) was considered the acquiring entity for accounting purposes, the Merger was structured so that RHS became a wholly-owned subsidiary of RGHS (formerly ASI).

F-11

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

Subsequent to, but related to, the Merger the Company entered into and became committed to a three-year employment agreement with Dr. Robertson who was appointed Chairman and CEO. The agreement provides for base compensation of $20,000 per month with an increase to $25,000 per month if the Company achieves an increase in gross revenues of $1,000,000 or more above gross revenues achieved during a previous fiscal quarter. In addition, Dr. Robertson was granted 100,000 in immediately exercisable “penny” warrants with a nominal exercise price. The Company has agreed to pay Dr. Robertson a grossed-up tax bonus sufficient to pay the resulting tax liability of the warrants (estimated and accrued at $140,000) and agreed to grant him stock options under the 2010 Stock Plan on at least 100,000 shares of common stock.

4. Property and Equipment

Property and equipment consisted of computer equipment and vehicles as follows:

	September 30,			September 30,
	2011			2010
Computer hardware	$	31,546		$	29,033
Vehicle		22,478			22,478
		54,024			51,511
Accumulated depreciation		(45,537	)		(47,397	)
Property and equipment, net	$	8,487		$	4,114

5. Real Estate and Installment Sale

Real Estate

At the time of the Merger, RGHS, through a wholly-owned subsidiary, owned three real estate properties held for investment and valued at $2,245,000. The three properties were recorded at management’s estimated fair value. The properties were held as an investment and evaluated for impairment at each reporting date.

In mid-June 2010, management determined and committed to a plan to sell the properties as soon as possible for cash to provide working capital for operations. Management believes its plan met the requirements of ASC 360-10-45-9 to reclassify the real estate as held for sale and valued the real estate on that basis. Given the stagnant nature of the unimproved land market in the Las Vegas area and limited cash buyers, management determined that the guidance of ASC 820-10-35-51A-D, Determining Fair Value When The Volume And Level Of Activity For The Asset Or Liability Have Significantly Decreased, was applicable and that a significant adjustment to historical transactions and historical appraised value on a held for investment basis was necessary to estimate the current fair value on a short-term cash held for sale basis. Management determined at that time that a sale at $900,000 or more would be acceptable and believed that would not be in excess of fair value and initiated an active program to seek cash buyers on this basis. As a result management recorded in June 2010 an impairment charge to reduce the carrying value of the real estate to $850,000 which included an allowance of $50,000 for the costs to sell in accordance with reclassification to held for sale.

In October 2010 management entered into an agreement, with an entity controlled by a former director, to sell the real estate and issue warrants to purchase up to 150,000 shares of the common stock at $2.50 per share for a term of five years (the “Warrants”) on an installment basis at a price of $900,000 payable over five months. As a result, management recorded in September 2010 an impairment charge to further reduce the carrying value of the real estate to $696,625, which reduced the costs to sell to $25,000 and included $178,375 for the value of the warrants. In January 2011 the Company received the final payment on installments totaling $900,000, net of $177,878 of closing costs, commissions and shareholder advances, and issued 150,000 Warrants. The fair value of the Warrants was computed at $178,375 using the Black-Scholes valuation model using a calculated volatility rate of 68.5% based on the historical volatility of comparable companies from a representative industry peer group, a risk free interest rate of 1.15%, and a contractual life equal to the term of the warrants expiring in 2015. A loss of $2,878, the amount of title and escrow charges on the sale, was recorded in November 2010.

F-12

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

Installment Sale

As a result of the management and operational changes resulting from the Merger, NxOpinion management negotiated as a term of the Merger transaction that the water rights held by ASI Land be sold to Davric Corporation (a related party at the time of the Merger), or assignee for $300,000. The terms of the sale, as amended by letter agreement dated June 15, 2010, required the payment of $100,000 by June 15, $100,000 by July 15 and the final $100,000 by August 15, 2010, with title to the rights transferring upon completion of the final installment. All payments were timely received by the Company and the installment sale was completed in August 2010.

The Company recorded the transaction as a sale in accordance with ASC 360-20, Real Estate Sales, effective June 15, 2010, and recorded no gain or loss on the sale. No interest was imputed on the deferred installments due to the short nature of the transaction.

6. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses include the following:

	September 30,		September 30,
	2011		2010
Accounts payable
Payable to unrelated parties	$	436,632	$	66,510
Payable to affiliate RRI for contract services (see Note 16)		511,520		516,144
Payable to related parties		30,000		1,625
Total accounts payable	$	978,152	$	584,279

Accrued liabilities
Accrued wages and vacation	$	348,133	$	192,206
Accrued bonus payable to CEO (see Note 3)		140,000		140,000
Other accounts payable		183,955		22,427
Total accrued liabilities	$	672,088	$	354,633

The Company’s obligation to RRI was reduced by $900,000 on May 28, 2010 as a result of the Merger related to past compensation for Dr. Robertson. Dr. Robertson received nominal exercise price warrants on 100,000 shares valued at $2.50 per share and is owed a tax bonus estimated at $140,000. The net reduction of $510,000 was recorded as a capital contribution.

7. Facility Exit Liability and Costs

Facility exit costs relate to an operating office lease that had been intended for use in real estate lending activities. A total of $166,845 was accrued as an exit liability in July 2009 in accordance with ASC 420, Exit or Disposal Cost Obligation. In June 2010 the Company entered into a sublease on the 3,747 feet of improved office space. The landlord granted a 50% rent concession for the six months ending December 2009, a 25% concession for the twelve months ending December 2010, and a 17% concession for the 10 months ending March 2012.

F-13

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

The following table summarizes facility exit liability activity for the year ended September 30, 2011 and for the period from the Merger (May 28, 2010) to September 30, 2010:

				Period from Merger
	Year Ended			(May 28, 2010) to
	September 30, 2011			September 30, 2010
Accrual balance beginning of period	$	82,154		$	66,574
Accrual correction for cash flow assumptions		1,085			29,012
Accretion expense		4,953			1,501
Payment - net		(55,863	)		(14,933	)
Accrual balance end of period	$	32,329		$	82,154

In the accompanying statement of operations, the expense for accrual corrections are included in other expenses, and all other facility exit costs and related accretion expense are included in selling, general and administrative expenses.

F-14

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

8. Notes Payable

Notes payable consist of the following:

			September 30,			September 30,
			2011			2010
Notes payable - related parties
Unsecured notes payable to related party directors with interest ranging from 10% to 18% with principal and interest due December 31, 2011. Includes accrued interest of $147,911 and $154,317, respectively. Net of note discount of $0 and $13,148, respectively.	(1	)	$	355,411		$	433,669

Unsecured notes payable to stockholders with interest ranging from 10% to 18% with principal and interest due December 31, 2011. Includes accrued interest of $13,611 and $23,228, respectively. Net of note discount of $0 and $2,922 respectively.	(2	)		43,611			85,306

Unsecured notes payable issued at Merger for prior consulting fees owed to two directors. Principal and interest at 5% per annum is due on December 31, 2011. Includes accrued interest of $16,322 and $4,164, respectively. Net of note discount of $0 and $10,933, respectively.	(3	)		259,497			236,406

Unsecured 11% note payable to a stockholder resulting from non-conversion of convertible note issued in April 2009. This note is currently in default with the default interest rate being 16%. Includes accrued interest of $17,445 and $9,445, respectively. (see Note 9)				67,445			59,445

Unsecured note payable to a company owned by the Company's CEO. Principal and interest at 15% per annum is due on December 15, 2011. Includes accrued interest of $1,849.				126,849			-

Total notes payable - related parties (current)			$	852,813		$	814,826

Notes payable - other current
Unsecured installment note, at 5% compounded monthly, with minimum monthly payments of $20,000 commencing July 2010. The balance is increased by additional invoices billed. This note is currently in default. Includes accrued interest of $10,569 and $0, respectively.	(4	)	$	513,782		$	476,743

Installment debt payable with interest at 11.24% per annum, with monthly installments of $3,026, due March 2012. Includes accrued interest of $0. Secured by gross unearned premiums and loss payments on the insurance policy financed.				17,236			-

Total notes payable - other current			$	531,018		$	476,743

Notes payable - other long-term
Five year term bank debt with interest at prime plus 1%, with monthly installments of $4,167 plus interest. Note is guaranteed by the Company's CEO. Includes accrued interest of $0 and $0, respectively.	(5	)		187,495			237,499

Less: Long-term portion of bank term debt				(137,495	)		(187,499	)

Notes payable - other (current portion)			$	50,000		$	50,000

F-15

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

Approximate principal repayments of long-term debt are as follows:

09/30/2012	$	50,000
09/30/2013		50,000
09/30/2014		50,000
09/30/2015		37,495

Total	$	187,495

(1)

Effective as of the Merger on May 28, 2010, new unsecured notes at the same interest rates were issued for previous secured notes with no stated repayment date. The Company issued warrants exercisable for 17,550 common shares at $2.50 per share until May 28, 2013 as an inducement for the note restructuring. The value of the warrants of $19,169 is a note discount which was amortized to interest expense over the original term of the notes. The Company has entered into Extension Agreements with the holders of the notes. Each lender has agreed to extend the original due date of June 30, 2011 to December 31, 2011 with no change to the interest rate or other terms of the notes.

(2)

Effective as of the Merger on May 28, 2010, new unsecured notes at the same interest rates were issued for previous secured notes with no stated repayment date. The Company issued warrants exercisable for 3,900 common shares at $2.50 per share until May 28, 2013 as an inducement for the note restructuring. The value of the warrants of $4,260 is a note discount which was amortized to interest expense over the original term of the notes. The Company has entered into Extension Agreements with the holders of the notes. Each lender has agreed to extend the original due date of June 30, 2011 to December 31, 2011 with no change to the interest rate or other terms of the notes.

(3)

The Company issued warrants exercisable for 14,591 common shares at $2.50 per share until May 28, 2013 as an inducement for converting consulting fees for unsecured notes. The value of the warrants of $15,937 is a note discount being amortized over the original term of the notes. The Company has entered into Extension Agreements with the holders of the notes. Each lender has agreed to extend the original due date of June 30, 2011 to December 31, 2011 with no change to the interest rate or other terms of the notes.

(4)

New unsecured note issued at Merger effective May 28, 2010, to replace prior secured notes and payables related to legal fees. In November 2011, the Company negotiated revised terms on this loan. The note is due on demand, but not later than June 1, 2012, including interest at 5% per annum. Payments are to be made as excess cash flow permits after covering only ordinary operating expenses. The note is secured by the Company assets.

(5)

The Company issued warrants exercisable for 15,000 common shares at $2.50 per share until May 28, 2013 as an inducement to Dr. Robertson for his continuing guarantee of a bank line of credit (due through affiliate RRI) that has been renegotiated as a term loan. The value of the warrants of $16,384 was a note discount expensed to interest at issuance as the note was due immediately until subsequently renegotiated as a five year term note.

In September 2011 the Company entered into Agreements with Company shareholders and directors to convert certain notes payable into shares of the Company’s common stock. A total of $120,000 of notes and accrued interest of $72,464 was converted at $1.00 per share into 192,464 shares of common stock.

In September 2011 the Company entered into Agreements to convert certain stockholder advances to shares of the Company’s common stock. A total of $150,000 of advances and accrued interest of $5,754 was converted at $1.00 per share into 155,754 shares of common stock.

9. Convertible Notes Payable

During 2009 the Company issued $250,000 of notes payable to two members of the Company. The notes accrued interest at 11% per annum, were due in April 2010 and were convertible with accrued interest into shares at $1.00 per share. In April 2010 a total of $200,000 of the notes and interest were noticed for conversion and the balance of $50,000 and related interest was not noticed and is now considered a debt obligation, past due included in notes payable (see Note 8). Prior to the Merger, 3,076 units became available for issuance and were issued in conversion of accrued interest of $3,076. In connection with the Merger the Company issued 214,223 shares of common stock for the conversion of the $200,000 convertible note and interest of $14,223.

F-16

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

During the quarter ended March 31, 2010 the Company issued $170,000 of 11% convertible notes payable. The Company also issued warrants exercisable on 170,000 shares exercisable at $2.50 per share until March 31, 2013. The fair value of the warrants of $89,048 was recorded as a liability due to insufficient member interest authorized and a beneficial conversion of $89,048 was recorded as a discount to the notes amortized as a non-cash expense over the term of the notes to June 30, 2010. At June 30, 2010 the notes and accrued interest of $5,698 was converted at $1.00 per share into 175,698 shares of common stock.

10. Stockholders’ Deficit

On February 16, 2010, the Board of Directors approved, and on February 22, 2010, a majority of shareholders consented to, an amendment to the RGHS articles of incorporation to increase the authorized shares of common stock to

301,000,000 shares, par value $0.001 per share, comprised of 300,000,000 shares of common stock and 1,000,000 shares of preferred stock. The amendment was effective May 18, 2010.

On June 4, 2010 the Company filed a certificate of change with the State of Nevada to effectuate a reverse stock split such that each 15 shares of common stock outstanding prior to the Reverse Split will be converted into one share of common stock and all options, warrants, convertible notes and any other similar instruments convertible into shares of common stock will be proportionally adjusted. The reverse split was effective on August 6, 2010.

As a result of the above, the Company has 20,000,000 shares of common stock, par value $0.001 authorized and 1,000,000 shares of preferred stock, par value $0.001, authorized. No preferred shares are outstanding. All share and dollar amounts in this report have been adjusted to retroactively reflect the reverse split and the current share structure.

The historical consolidated financial statements also reflect the impact of the change in capital structure that resulted from the Merger as if that capital structure was in place as of April 11, 2005 (date of inception) and for all subsequent periods presented. Accordingly, the accompanying consolidated balance sheet as of September 30, 2010, and the accompanying consolidated statements of stockholders’ equity for the period from April 11, 2005 (date of inception) to September 30, 2011 have been adjusted to reflect the current capital structure of the Company. In financial statements published prior to the Merger, references to the previous capital structure were to members’ capital rather than stockholders’ equity.

The Company recognized a capital contribution of $510,000 at May 28, 2010 in accordance with ASC 470-50-40-2 related to the cancellation of $900,000 of debt owed to an affiliated entity through common management offset by the value of warrants and a tax bonus granted in connection with such warrants all as more fully described in Note 6.

11. Stock Options and Stock Purchase Warrants

Stock Option Plan

In February 2010, the Board and Stockholders of RGHS approved the Stock Incentive Plan of 2010 (the “2010 Incentive Plan”) authorizing the grant of equity-based incentives to employees and consultants including stock options, stock appreciation rights, restricted stock units, restricted stock, stock awards and other awards on the lesser of (a) on a cumulative basis 15% of the aggregate shares of the Company’s common stock issued and outstanding at any grant date (currently limited to the maximum 1,400,000 shares) or (b) 1,400,000 shares. The Incentive Plan terminates in February 2020.

NxOpinion had no option plans prior to the Merger. The Company continued 25,012 legacy options under ASI’s 2000 Plan at the Merger and the 2000 Plan has expired as to new grants.

Stock-Based Compensation

The Company’s employee stock options have various restrictions that reduce option value, including vesting provisions and restrictions on transfer, among others, and may be exercised prior to their contractual maturity.

The Company uses the Black-Scholes option pricing model to determine the estimated fair value of each option as of its grant date. These inputs are subjective and generally require significant analysis and judgment to develop. The following table sets forth the significant assumptions used in the Black-Scholes model and the calculation of stock-based compensation cost (annualized percentages):

F-17

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

	Year Ended	Nine Months Ended
	September 30, 2011	September 30, 2010
Expected volatility	73.02%	71.00%
Risk-free interest rate	1.60%	1.14%
Forfeiture rate	0.0% - 5.0%	0.0% - 5.0%
Dividend yield	0.00%	0.00%
Expected life in years	4.48	4.2

Since the Company’s stock is not actively traded and the merger changed the nature of the Company’s business, the Company’s management estimated its expected volatility by reviewing the historical volatility of the common stock of a group of selected peer public companies that operate in similar industries and are similar in terms of stage of development or size and then projecting this information toward its future expected results. Judgment was used in selecting these companies, as well as in evaluating the available historical volatility for these peer companies. The risk-free interest rate is based on rates published by the Federal Reserve Board. The dividend yield of zero is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. The Company has a small number of option grants and no significant exercise history and accordingly has for all new option grants applied the simplified method prescribed by SEC Staff Accounting Bulletin 110, Share-Based Payment: Certain Assumptions Used in Valuation Methods - Expected Term, to estimate expected life (computed as vesting term plus contractual term divided by two). An estimated forfeiture rate was derived from the Company’s historical employee data and its estimates of the likely future actions of option holders. Forfeitures are estimated at the time of the grant and revised in subsequent periods if actual forfeitures differ from those estimates or if the Company updates its estimated forfeiture rate. Such amounts will be recorded as a cumulative adjustment in the period in which the estimate is changed.

The Company recorded $656,353 and $308,602 of stock compensation expense for the year ended September 30, 2011 and the nine months ended September 30, 2010, respectively. There were no stock options outstanding prior to the merger on May 28, 2010. The weighted-average estimated fair value of employee and consultant stock options granted during the year ended September 30, 2011 and the nine months ended September 30, 2010 was $1.82 per share and $1.65 per share, respectively.

As of September 30, 2011 total estimated compensation cost of options granted but not yet vested was approximately $292,894 and is expected to be recognized over the weighted average period of 1.1 years.

Stock Option Summary Information

The following table summarizes stock option activity for the year ended September 30, 2011 and the nine months ended September 30, 2010:

F-18

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

	September 30, 2011								September 30, 2010
				Weighted-		Aggregate		Weighted-				Weighted-		Aggregate		Weighted-
				Average		Intrinsic		Average				Average		Intrinsic		Average
				Exercise		Value		Life				Exercise		Value		Life
	Shares			Price		(3)		(Years)	Shares			Price		(2)		(Years)
Outstanding beginning of period		590,078		$	3.22					-
Assumed May 28, 2010 from Merger		-								25,012		$	5.41
Granted		190,000		$	3.62					566,400		$	3.13
Exercised		(600	)	$	3.00					-
Cancelled		(4,902	)	$	5.45					(1,334	)	$	5.25
Outstanding end of period (1)		774,576		$	3.33		-	4.0		590,078		$	3.22		153,960	4.8
Options exercisable at end of period		516,616		$	3.14		-	3.9		216,958		$	3.44		40,072	4.6

(1)

Options outstanding are exercisable at prices ranging from $2.20 to $6.75 and expire over the period 2011 to 2016.

(2)

Aggregate intrinsic value is based on the closing price of the Company’s common stock on September 30, 2010 of $3.40.

(3)

Aggregate intrinsic value is based on the closing price of the Company’s common stock on September 30, 2011 of $2.20.

The following table summarizes information about stock options outstanding at September 30, 2011:

Range of exercise prices	Number outstanding at September 30, 2011		Number exercisable at September 30, 2011		Weighted average exercise price		Weighted average remaining contractual life		Weighted average exercise price of options exercisable at September 30, 2011
$	#		#		$		Years		$
$2.20 - $3.00		390,401		275,841		2.80		4.0		2.71
$3.30 - $3.40		278,500		207,100		3.34		3.9		3.33
$3.75 - $6.75		105,675		33,675		5.30		4.1		5.52

Warrants

In connection with the sale of certain membership interests for cash at $1.00 per unit during 2009, the Company granted the investors the right to purchase an additional unit at $1.00 per unit through December 31, 2014. A total of 416,000 warrants were issued during the year and subsequently in January 2010 the Company granted an additional 125,000 warrants for a total of 541,000 warrants. Until the Merger, the Company did not have sufficient equity interests authorized for exercise of the warrants.

The Company determined in accordance with ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, that insufficient member interests available for exercise of the warrants prevented the instruments from being indexed to the Company’s equity requiring liability treatment. The fair value of the warrants granted was determined using the Black-Scholes valuation model using the price of recent private sales of member’s equity, a calculated volatility rate of 65% based on the historical volatility of comparable companies from a representative industry peer group, risk free interest rates ranging from 1.99% to 2.73%, and a contractual life equal to the remaining term of the warrants expiring December 31, 2014.

F-19

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

The warrant fair value was adjusted each reporting period based on current assumptions, with the change in value recognized in earnings and reported as other income (expense). The warrant fair value of the 541,000 warrants and the 170,000 convertible note warrants (Note 9) at May 28, 2010 was $379,922 and was reclassified to equity at that date. The Company recorded a gain on revaluation of $12,658 during the nine months ended September 30, 2010.

The same Black-Scholes valuation methodology as described above, adjusted for the term of the respective warrants, was used to value the warrants issued with convertible notes (Note 9) and warrants granted in connection with debt restructuring (Notes 3 and 8).

The following table summarizes warrant activity for the nine months ended September 30, 2010 and the year ended September 30, 2011:

				Average
				Exercise Price
	Number			Per Share
Shares purchasable under outstanding warrants at January 1, 2010		416,000		$	1.00
Stock purchase warrants granted with equity sales		125,000		$	1.00
Stock purchase warrants granted with convertible notes		170,000		$	2.50
Stock purchase warrants granted in connection with debt restructuring		51,041		$	2.50
Stock purchase warrants granted for prior services		100,000		$	0.01
Shares purchasable under outstanding warrants at September 30, 2010		862,041		$	1.27
Stock purchase warrants granted in connection with land sale		150,000		$	2.50
Stock purchase warrants granted with equity sales		75,000		$	1.00
Stock purchase warrants exercised		(75,000	)	$	1.00
Shares purchasable under outstanding warrants at September 30, 2011		1,012,041		$	1.45

At September 30, 2011 the Company had the following warrants outstanding:

	Number of		Exercise Price
Description	Common Shares		Per Share		Expiration Date
Warrants		541,000	$	1.00	December 31, 2014
Warrants		170,000	$	2.50	March 31, 2013
Warrants (1)		51,041	$	2.50	May 28, 2013
Warrants (2)		100,000	$	0.01	May 28, 2013
Warrants		50,000	$	2.50	October 22, 2015
Warrants		50,000	$	2.50	November 12, 2015
Warrants		50,000	$	2.50	January 12, 2016
		1,012,041

(1)

A total of 32,141 of these warrants are held by directors.

(2)

These 100,000 warrants are held by the Company’s Chief Executive Officer.

12. Simple IRA

Beginning in July 2010, the Company sponsors a Simple IRA plan that is available to all employees who receive at least $5,000 in compensation. The plan permits salary deferrals to be made by the employees and an employer matching contribution up to 3% of compensation. The Company’s matching contribution charged to expense for the year ended September 30, 2011 and the nine months ending September 30, 2010 was $23,249 and $4,194, respectively.

Prior to July 2010, personnel were employed by Robertson Research Institute (RRI) (see Note 16) and participated in the Robertson Research Institute Simple IRA plan. These costs were included in personnel costs charged by RRI and are included in the appropriate functional line items in the Company’s consolidated statement of operations.

F-20

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

13. Operating Lease

On July 1, 2010, the Company entered into a two year operating lease for office space at 4215 Fashion Square Blvd., Suite 3, Saginaw, Michigan. The base monthly rent payments are approximately $5,562. In addition to the base rent payment, a monthly allocation for taxes, insurance, maintenance, utilities, and services is payable to the lessor, currently $1,600 per month, for a total rent payment of $7,162. The lease is renewable by the Company for an additional two year period under the same terms and conditions. Rent expense during the year ended September 30, 2011 and the nine months ended September 30, 2010 was $85,950 and $64,463, respectively. Approximate future commitments under this agreement are as follows:

09/30/2012

64,458

14. Fair Value Measurements

The carrying amounts of cash and equivalents, receivables and accounts payable approximate fair values due to the short-term maturities of these instruments.

ASC 820-10, Fair Value Measurements and Disclosures, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company had no financial assets or liabilities measured at fair value on a recurring basis at September 30, 2011 or 2010.

As described in Note 11, the Company had warrants issued in 2009 and 2010 for which there were not sufficient equity interest available for exercise. In accordance with ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, the Company classified the fair value of each warrant at issuance as a liability. The Company used Level 3 inputs for its valuation methodology and the fair value was determined by using the Black-Scholes option pricing model based on various assumptions including significant unobservable inputs developed by management regarding peer company volatility and unit price.

The following table reconciles the warrant derivative liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the nine months ended September 30, 2010:

Balance at January 1, 2010	$	234,035
Issuance of new warrant derivatives from sale of member units		69,497
Issuance of new warrant derivatives in connection with convertible notes		89,048
Adjustment to fair value included in other income		(12,658	)
Reclassification of warrant liability to equity		(379,922	)
Balance at September 30, 2010	$	-

The Company had no warrant derivative activity during the year ended September 30, 2011.

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

The Company had no financial assets or liabilities measured at fair value on a nonrecurring basis at September 30, 2011. Assets measured at fair value on a nonrecurring basis as of September 30, 2010 are included in the table below:

F-21

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

			Fair Value Measurements Using
			Quoted Prices		Significant
			in Active		Other		Significant
			Markets for		Observable		Unobservable
			Identical Assets		Inputs		Inputs		Total Gains
	Total		Level 1		Level 2		Level 3		(Losses)
September 30, 2010:
Assets:
Real estate held for sale	$	696,625	$	-	$	-	$	696,625	$	(1,548,375	)
Liabilities:
None	$	-	$	-	$	-	$	-	$	-

The Company measured the foregoing assets at estimated fair value on a nonrecurring basis from time to time only when deemed to be impaired in accordance with U.S. generally accepted accounting principles. Likewise the Company periodically evaluates the facts and assumptions used to estimate the fair value of its facility exit liability (Note 7).

Real estate owned consisted of three parcels of undeveloped land (Note 5) obtained through deeds in lieu of foreclosure by RGHS in December 2009. Each parcel was recorded at management’s estimated fair value based on Level 3 unobservable inputs including current and prior appraisals, comparable local sales data, and where applicable adjustments to reflect the highest and best use of each parcel. Highest and best use adjustments reflected zoning changes or parcel subdivisions that were possible and probable, legally permissible and financially feasible at the measurement date computed using comparable sales data and consultation with appraisal and development professionals. Subsequently in June 2010 the parcels were reclassified as held for sale and impairment recorded as described in Note 5.

15. Income Taxes

Prior to the Merger, the Company was organized as a limited liability company, was accounted for like a partnership for federal and state income tax purposes and generally did not incur income taxes. Instead, the Company’s earnings and losses were included in the income tax returns of its members. Therefore, no provision or liability for federal income taxes has been included in the financial statements for the operations prior to the Merger.

Due to the Merger transaction, NxOpinion is now treated as a corporation for income tax purposes and will be taxed as such for the earnings during the period beginning May 29, 2010. The Company has incurred losses for each of the periods since its inception and since the Merger. The tax attributes of the legal acquirer (RGHS) prior to the merger included approximately $2,950,000 of net operating losses whose benefits may be substantially limited due to the change in ownership. Those prior Merger losses and losses of the Company after the Merger since being taxable as a corporation have appropriately been recorded as a deferred tax asset with an offsetting valuation allowance as the losses are not more likely than not to be utilized prior to their expiration. Accordingly, no tax provision or benefit was recognized during each of the periods presented.

Differences between the income tax provision (benefit) computed at the statutory federal income tax rate and per the consolidated statements of operations are summarized as follows:

	Twelve Months			Nine Months
	Ended			Ended
	September 30,			September 30,
	2011			2010
Income taxes (benefit) computed at federal statutory rate	$	(955,000	)	$	(1,216,000	)
NxOpinion LLC results not subject to corporate income taxes		-			342,000
Corporate losses prior to Merger		-			(121,000	)
Permanent book-tax differences		64,000			228,000
Deferred income tax valuation allowance		891,000			767,000
Income tax provision	$	-		$	-

F-22

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

Deferred federal income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities are as follows:

	September 30,
	2011			2010
Deferred tax assets
Net operating loss carryforwards	$	2,669,000		$	1,408,000
Impairment and bad debt reserves		-			526,000
Stock-based compensation		345,000			169,000
Accruals and other		58,000			77,000
		3,072,000			2,180,000
Deferred tax liabilities
Depreciation and amortization		(1,000	)		-
		3,071,000			2,180,000
Valuation allowances for deferred tax assets		(3,071,000	)		(2,180,000	)
Net deferred taxes	$	-		$	-

As of September 30, 2011, the Company had federal net operating loss (“NOL”) carryforwards of approximately $7,838,000. These losses will expire in years 2025 through 2031 and the use of any such NOLs may be subject to substantial annual limitation under Section 382 of the Internal Revenue Code and similar state provisions, due to changes in ownership of the Company that have occurred previously and may occur in the future.

The Company continues to maintain a valuation allowance against the value of all deferred tax assets at September 30, 2011 due to the uncertainty of realizing these assets in the future. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment.

In June 2006, the FASB issued guidance in regard to the recognition of tax benefits for positions claimed or to be claimed in tax returns. Management has evaluated the tax positions claimed and expected to be claimed in its tax returns and has concluded that all positions are more likely than not to be sustained upon examination by applicable taxing authorities. Management has also concluded that no liability for uncertain tax positions should be recorded as of September 30, 2011. The Company is subject to U.S. federal tax examinations for tax years through 2011, subject to the statute of limitations. The Company has no income tax examinations in process.

Pro forma tax and net loss per share amounts in accordance with Article 11 of Regulation S-X are not presented on the statement of operations as there was no pro forma difference since there was no tax provision for the periods covered by this report.

16. Related Party Transactions

Since its formation, the Company has contracted with Robertson Research Institute (“RRI”), a nonprofit entity organized under Section 501(c)3 of the Internal Revenue Code, for software and content development and corporate operational services including personnel, occupancy and other vendor costs. After the Merger, the Company transitioned these services back to the Company. These services are billed to the Company by RRI on a flow-through basis and at cost with certain personnel costs allocated based on percentage of time spent on Company efforts. During the year ended September 30, 2010 substantially all of the services of RRI personnel were charged to the Company by RRI, including the services of the Company’s CEO, Dr. Joel Robertson, through the date of the Merger. Dr. Robertson is also a Trustee of RRI. Certain expenses continue to be paid by RRI and are charged to the Company at cost as incurred.

F-23

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

During the twelve months ended September 30, 2011 and 2010 (unaudited) and for the nine months ended September 30, 2010 the Company incurred costs billed by RRI detailed as follows:

					Nine Months
	Twelve Months Ended				Ended
	September 30,				September 30,
	2011		2010		2010
			(Unaudited)
Personnel and benefits	$	77	$	908,751	$	603,666
Professional fees		5,355		185,448		185,195
Occupancy		7,826		106,220		61,948
Travel and entertainment		77,399		51,131		36,016
Marketing		874		6,309		5,961
Insurance		-		54,364		49,025
Interest		7,800		18,014		11,585
Computer and software		5,105		10,159		2,635
Consulting and contract services		-		12,733		9,608
Other		24,956		31,645		26,429
	$	129,392	$	1,384,774	$	992,068

These amounts are included in the appropriate functional line items in the Company’s statement of operations. Amounts payable to RRI for such services at September 30, 2011 and 2010 are listed in Note 6.

After the merger, certain employees have been contracted on an as needed basis by Robertson Wellness, LLC (“RW”), a company owned by the Company’s CEO, Dr. Joel Robertson. These personnel costs are allocated to RW at cost based on percentage of time spent on RW efforts. The total amount allocated to RW during the year ended September 30, 2011 and the nine months ended September 30, 2010 was $39,241 and $3,842, respectively.

See additional related party information in Notes 3, 5, 8, 9, and 11.

17. Commitments and Contingencies

Going Concern

The Company incurred significant losses during the last two fiscal periods and as a result it has limited funds and liquidity with which to operate. The Company’s operating plans will require additional funds. Additional funds may be obtained in the form of debt or equity financings. During the balance of fiscal 2012, the Company may elect to incur additional costs to develop its business. The Company may also seek or pursue other business opportunities. However, there can be no assurance that sufficient additional funds will be available to enable the Company to continue as a going concern. Although asset impairment adjustments have been made in accordance with generally accepted accounting principles, the accompanying consolidated financial statements do not include any adjustments that would be necessary should the Company be unable to continue as a going concern and, therefore, be required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying financial statements.

Employment Agreement

In June 2010, the Company entered into a three-year employment agreement with Dr. Robertson to serve as President and Chief Executive Officer. The agreement provides for base compensation of $20,000 per month with an increase to $25,000 per month if the Company achieves an increase in gross revenues of $1,000,000 or more above gross revenues achieved during the previous fiscal quarter.

F-24

ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES

(a development stage company)

Notes to Consolidated Financial Statements

Facility Leases

As a result of the Merger, the Company is committed pursuant to an operating lease on 3,747 square feet of office space in Las Vegas, Nevada providing for current monthly payments of $7,494 through lease termination in March 2012. In August 2011 the Company sublet the space on a month-to-month basis for up to the term of the main lease at a rate of $2,000 per month. Assuming the sublease does not extend beyond December 2011 the total future commitment pursuant to this lease is $38,964.

Nevada		88-0105586
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

ITEM 1.	Business	1
ITEM 1A.	Risk Factors	14
ITEM 1B.	Unresolved Staff Comments	19
ITEM 2.	Properties	20
ITEM 3.	Legal Proceedings	20
ITEM 4.	(Removed and Reserved)	20

ITEM 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	20
ITEM 6.	Selected Financial Data	22
ITEM 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
ITEM 7A.	Quantitative and Qualitative Disclosures about Market Risk	27
ITEM 8.	Financial Statements and Supplementary Data	27
ITEM 9.	Changes In and Disagreement With Accountants on Accounting and Financial Disclosure	27
ITEM 9A	Controls and Procedures	27
ITEM 9B.	Other Information	28

ITEM 10.	Directors, Executive Officers and Corporate Governance	28
ITEM 11.	Executive Compensation	30
ITEM 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	32
ITEM 13.	Certain Relationships and Related Transactions and Director Independence	34
ITEM 14.	Principal Accounting Fees and Services	35

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)		Weighted-average exercise price of outstanding options, warrants and rights (b)		Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c)
Equity compensation plans approved by security holders (1)		774,576		$ 3.33		645,100
Equity compensation plans not approved by security holders		-0-		-		-0-
Total		774,576		$ 3.33		645,100

ITEM 15.	Exhibits and Financial Statement Schedules	35
	Financial Statements	F-1
	Signatures

	Bid Quotations
	High		Low
Year Ended September 30, 2011
First Quarter	$	0.00	$	0.00
Second Quarter	$	0.00	$	0.00
Third Quarter	$	0.00	$	0.00
Fourth Quarter	$	0.00	$	0.00

Nine Months Ended September 30, 2010
First Quarter	$	0.00	$	0.00
Second Quarter	$	5.625	$	0.00
Third Quarter	$	4.50	$	0.00

Name	Age	Position(s)		Director Since
Joel C. Robertson	59	Director, Chairman, President and Chief Executive Officer	May 2010
Melissa A. Seeger	38	Chief Financial Officer, Treasurer and Secretary
Gerald L. Ehrens	72	Director	September 2005
Peter J. Perkinson	68	Director	July 2010

								All Other
						Option		Compensation
Name and	Reporting	Salary (1)		Bonus		Awards (3)		(2)		Total
Principal Position	Period	($)		($)		($)		($)		($)

Joel C. Robertson, Chairman, President and Chief Executive Officer (PEO)	Year Ended September 30, 2011	$	249,231	$	-	$	18,017	$	9,727	$	276,975
	Transition Period ended September 30, 2010	$	60,000	$	-	$	120,334	$	251,108	$	431,442

Melissa A. Seeger, Secretary and Treasurer (PFO)	Year Ended September 30, 2011 (4)	$	119,865	$	-	$	9,222	$	1,814	$	130,901
	Transition Period ended September 30, 2010	$	14,560	$	-	$	7,285	$	336	$	22,181

	Fees
	Earned
	or Paid		Option		All Other
	in Cash		Awards (1)		Compensation		Total
Name	($)		($)		($)		($)

Gerald L. Ehrens		-	$	14,148		-	$	14,148
Peter Perkinson			$	139,291			$	139,291

Title of Class	Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership (1)		Percent of Class

Common Stock	Joel C. Robertson	6,094,808	(2)	48.5%
	4215 Fashion Square Blvd., Suite 3
	Saginaw, Michigan 48603

Common Stock	Melissa A. Seeger	16,000	(3)	*
	4215 Fashion Square Blvd., Suite 3
	Saginaw, Michigan 48603

Common Stock	Gerald L. Ehrens	606,139	(4)	4.9%
	4215 Fashion Square Blvd., Suite 3
	Saginaw, Michigan 48603

Common Stock	Peter J. Perkinson	263,752	(5)	2.1%
	4215 Fashion Square Blvd., Suite 3
	Saginaw, Michigan 48603

Common Stock	Michael J. Jandernoa	986,023	(6)	7.8%
	c/o Perrigo Co, 333 Bridge St. NW, #800
	Grand Rapids, Michigan 49504

Common Stock	Marilyn H. Hite	792,962	(7)	6.4%
	7260 W. Azure Dr, #140-302
	Las Vegas, Nevada 89130

Common Stock	Jerry E. Polis	768,705	(8)	6.1%
	980 American Pacific Drive, #111
	Henderson, Nevada 89014

	All directors and executive	6, 980,699		54.7%
	officers as a group (4 persons)

*	less than 1%.
(1)	Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares beneficially owned. Unless otherwise specified, reported ownership refers to both voting and investment power. Stock options, warrants and convertible securities which are exercisable within 60 days are deemed to be beneficially owned. On December 20, 2011, there were 12,352,187 shares of common stock issued and outstanding.
(2)	Includes 5,871,808 shares owned by JVR Technologies, LLC, a Nevada limited liability company owned 50%/50% by Joel C. Robertson and his wife Vickie Robertson. The amount shown as beneficially owned by Joel C. Robertson reflects 100% of the common stock of the Company owned by JVR Technologies, LLC. Also includes 115,000 warrants and 108,000 options.
(3)	Consists solely of stock options.
(4)	Includes 460,000 shares owned by family limited partnership, 23,300 warrants and 19,334 options.
(5)	Includes 60,000 shares held by IRA, 8,841 warrants and 116,000 options.
(6)	Consists of 741,023 shares and warrants on 245,000 shares held by the Michael J. Jandernoa Trust based on information provided by the stockholder as of February 14, 2011.
(7)	Shares held by The Marisite Family Trust based on information provided by the stockholder as of June 8, 2010.
(8)	Beneficial ownership based on information provided by the stockholder as of January 24, 2011. Consists of 591,037 shares, 2,668 options and 175,000 warrants. A total of 342,914 shares are held by a family trust, 229,457 shares by a controlled corporation and 18,666 shares by a family LLC. A total of 150,000 warrants are held by an LLC over which Mr. Polis executes voting and investment control but disclaims beneficial ownership other than his pecuniary interest in the LLC.

Report of Independent Registered Public Accounting Firm	F-1
Consolidated Balance Sheets as of September 30, 2011 and September 30, 2010	F-2
Consolidated Statements of Operations for the Year Ended September 30, 2011, the Nine Months Ended September 30, 2010, and the period from inception (April 11, 2005) to September 30, 2011	F-3
Consolidated Statements of Stockholders’ Equity (Deficit) for the period from inception (April 11, 2005) to September 30, 2011	F-4
Consolidated Statements of Cash Flows for the Year Ended September 30, 2011, the Nine Months Ended September 30, 2010, and the period from inception (April 11, 2005) to September 30, 2011	F-5
Notes to Consolidated Financial Statements	F-6

	September 30,			September 30,
ASSETS	2011			2010
Current assets
Cash	$	90,585		$	40,976
Accounts receivable		41,500			-
Accounts receivables - related parties		47,031			8,842
Prepaid and other		35,663			27,268
Total current assets		214,779			77,086

Property and equipment, net		8,487			4,114
Real estate held for sale, net		-			696,625

Total assets	$	223,266		$	777,825

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable	$	978,152		$	584,279
Accrued liabilities		672,088			354,633
Deposits		-			3,747
Related party deferred revenue		-			207,416
Deferred revenue		31,500			-
Stockholder advances		-			150,000
Notes payable related parties - net		852,813			814,826
Notes payable other - net		531,018			476,743
Current portion of facility exit liability		32,329			51,056
Current portion bank term note		50,000			50,000
Total current liabilities		3,147,900			2,692,700

Long-term debt
Bank term note		137,495			187,499
Facility exit liability		-			31,098
Total long-term debt		137,495			218,597

Stockholders' deficit
Preferred stock, $0.001 par value, 1,000,000 shares authorized, none issued and outstanding		-			-
Common stock, $0.001 par value, authorized 20,000,000, 12,352,187 and 11,543,369 shares issued and outstanding, respectively		12,352			11,543
Paid-in capital		13,801,666			11,922,729
Deficit accumulated during development stage		(16,876,147	)		(14,067,744	)
Total stockholders' deficit		(3,062,129	)		(2,133,472	)

Total liabilities and stockholders' deficit	$	223,266		$	777,825

				Twelve-Month			Nine-Month			April 11, 2005
				Comparative			Transition			(date of
	Year Ended			Period Ended			Period Ended			inception) to
	September 30,			September 30,			September 30,			September 30,
	2011			2010			2010			2011
				(Unaudited)
Revenues
Contract fees	$	10,000		$	133,000		$	-		$	143,000
Contract fees - related party		207,416			-			-			207,416
Total revenues		217,416			133,000			-			350,416

Operating expenses
Cost of revenues		-			139,536			-			139,536
Product and content development		1,004,352			628,634			522,908			6,548,309
Selling, general and administrative		1,902,019			1,650,209			1,363,027			8,556,705
Impairment expense on real estate held for sale		-			1,548,375			1,548,375			1,548,375
Total operating expenses		2,906,371			3,966,754			3,434,310			16,792,925
Operating loss		(2,688,955	)		(3,833,754	)		(3,434,310	)		(16,442,509	)

Other income (expense)
Unrealized gain on derivative revaluation		-			14,693			12,658			17,279
Interest and other income		38,390			15,254			15,254			348,624
Other expenses		(3,964	)		(29,953	)		(29,953	)		(97,236	)
Interest expense		(153,874	)		(322,872	)		(299,080	)		(702,305	)
Total other income (expense)		(119,448	)		(322,878	)		(301,121	)		(433,638	)

Net loss	$	(2,808,403	)	$	(4,156,632	)	$	(3,735,431	)	$	(16,876,147	)

Loss per share (basic)	$	(0.24	)	$	(0.40	)	$	(0.35	)	$	(1.64	)

Weighted average number of common shares outstanding		11,664,382			10,508,711			10,680,144			10,315,632

							Additional						Total
	Common Stock						Paid-In			Accumulated			Equity
	Shares			Dollars			Capital			Deficit			(Deficit)

Balances, April 11, 2005 (date of inception)		-		$	-		$	-		$	-		$	-

Stock issued to founder for technology		9,600,000			9,600			(9,600	)		-			-
Founder stock assigned to director		290,000			290			(290	)		-			-
Sale of stock for cash at $2.50 to $3.25 per share		1,156,000			1,156			3,348,844			-			3,350,000
Forfeiture of founder stock - net		(1,046,000	)		(1,046	)		1,046			-			-
Net loss		-			-			-			(1,373,347	)		(1,373,347	)
Balances, December 31, 2005		10,000,000		$	10,000		$	3,340,000		$	(1,373,347	)	$	1,976,653

Sale of stock at $2.50 to $4.00 per share		456,500			456			1,759,544			-			1,760,000
Repurchase of stock at $2.50 per share		(144,000	)		(144	)		(359,856	)		-			(360,000	)
Forfeiture of founder stock - net		(312,500	)		(312	)		312			-			-
Net loss		-			-			-			(3,488,381	)		(3,488,381	)
Balances, December 31, 2006		10,000,000		$	10,000		$	4,740,000		$	(4,861,728	)	$	(111,728	)

Sale of stock at $2.00 to $6.00 per share		414,038			414			1,089,586			-			1,090,000
Forfeiture of founder stock		(414,038	)		(414	)		414			-			-
Net loss		-			-			-			(2,451,762	)		(2,451,762	)
Balances, December 31, 2007		10,000,000		$	10,000		$	5,830,000		$	(7,313,490	)	$	(1,473,490	)

Sale of stock at $2.00 to $3.25 per share		658,154			658			1,158,342			-			1,159,000
Forfeiture of founder stock		(658,154	)		(658	)		658			-			-
Net loss		-			-			-			(1,443,771	)		(1,443,771	)
Balances, December 31, 2008		10,000,000		$	10,000		$	6,989,000		$	(8,757,261	)	$	(1,758,261	)

Sale of stock at $1.00 per share		428,500			428			428,072			-			428,500
Classification of 416,000 warrants as a liability		-			-			(238,656	)		-			(238,656	)
Forfeiture of founder stock		(428,500	)		(428	)		428			-			-
Net loss					-			-			(1,575,052	)		(1,575,052	)
Balances, December 31, 2009		10,000,000		$	10,000		$	7,178,844		$	(10,332,313	)	$	(3,143,469	)

Sale of stock at $1.00 per share		125,000			-			125,000			-			125,000
Classification of 125,000 warrants as a liability		-			-			(69,497	)		-			(69,497	)
Forfeiture of founder stock		(125,000	)		-			-			-			-
Record beneficial conversion of $170,000 of convertible notes		-			-			89,048			-			89,048
Redemption of stock		(3,076	)		(3	)		(11,997	)		-			(12,000	)
Shares issued on conversion of convertible debt at $1.00 per share		3,076			3			3,073			-			3,076

Merger related equity transactions:
Historical ASI Technology shares		1,154,248			1,154			2,718,773			-			2,719,927
Shares issued on conversion of convertible debt at $1.00 per share		214,223			214			214,009			-			214,223
Reclassification of warrant liability to equity								379,922			-			379,922
Value of 100,000 warrants issued to founder related to debt extinguishment								250,000			-			250,000
Capital contribution from related party debt extinguishment								510,000			-			510,000
Value of 51,041 warrants issued to stockholders related to debt restructuring and guarantee								55,750			-			55,750

Shares issued on conversion of convertible debt at $1.00 per share		175,698			176			175,522			-			175,698
Payment of fractional shares on reverse stock split		(800	)		(1	)		(4,320	)					(4,321	)
Stock based compensation								308,602						308,602
Net loss											(3,735,431	)		(3,735,431	)
Balances, September 30, 2010		11,543,369		$	11,543		$	11,922,729		$	(14,067,744	)	$	(2,133,472	)

Sale of stock at $2.00 per share		235,000			235			469,765			-			470,000
Sale of stock at $1.00 per share		150,000			150			149,850						150,000
Shares issued on conversion of debt at $1.00 per share		348,218			348			347,870						348,218
Exercise of warrants at $1.00 per share		75,000			75			74,925						75,000
Value of 150,000 warrants issued related to sale of real estate held for sale								178,375						178,375
Stock based compensation								656,353						656,353
Stock option exercise		600			1			1,799						1,800
Net loss		-			-			-			(2,808,403	)		(2,808,403	)
Balances, September 30, 2011		12,352,187		$	12,352		$	13,801,666		$	(16,876,147	)	$	(3,062,129	)

Exhibit Number	Description
2.1	Original Letter Agreement dated October 13, 2010 (incorporated by reference from Exhibit 10.1 to the Company’s Current Report Form 8-K dated October 19, 2010).
2.2	Letter dated October 20, 2010 confirming amendment to Original Letter Agreement dated October 13, 2010 (previously filed as Exhibit 2.2 to our Current Report on Form 8-K filed on October 26, 2010 and incorporated herein by reference).
3.1	Articles of Incorporation, as currently in effect (previously filed as Exhibit 3.1 to our Quarterly Report on Form 10-Q filed on August 16, 2010 and incorporated herein by reference).
3.2	Amended and Restated Bylaws (previously filed as Exhibit 3.01 to our Current Report on Form 8-K filed on June 4, 2010 and incorporated herein by reference).
10.1	Sublease dated as of October 11, 2007 between ASI Capital Corporation and Joseph L. Lamarca and Jerry E. Polis (previously filed as Exhibit 99.1 to our Current Report on Form 8-K filed on November 9, 2007 and incorporated herein by reference).
10.2	Letter Agreement dated October 13, 2010 regarding sale of parcels and exhibit thereto (previously filed as Exhibit 10.1 to our Current Report on Form 8-K filed on October 19, 2010 and incorporated herein by reference).
10.3	Letter dated October 20, 2010 confirming amendment to Original Letter Agreement dated October 13, 2010 (previously filed as Exhibit 2.2 to our Current Report on Form 8-K filed on October 26, 2010 and incorporated herein by reference).
10.4	Product Distribution Agreement between Robertson Technologies Licensing, LLC and Montana Healthcare Solutions PTY Ltd effective December 6, 2010 (previously filed as Exhibit 10.1 to our Current Report on Form 8-K filed on December 10, 2010 and incorporated herein by reference).
10.5	Sanlam Health Addendum to Product Distribution Agreement between Robertson Technologies Licensing, LLC and Montana Healthcare Solutions PTY Ltd effective December 6, 2010 (previously filed as Exhibit 10.2 to our Current Report on Form 8-K filed on December 10, 2010 and incorporated herein by reference).
10.6	Letter Agreement dated April 18, 2011 regarding the extending and amending of the Standard Sublease entered into on April 12, 2010 (previously filed as Exhibit 10.2 to our Current Report on Form 8-K filed on April 20, 2011 and incorporated herein by reference).
10.7	Form of Promissory Note Extension Agreements due September 30, 2011 with interest rates of 10% to 18% between the Company and five creditors dated June 30, 2011 for an aggregate principal amount of $357,500 (previously filed as Exhibit 10.1 to our Current Report on Form 8-K filed on July 7, 2011 and incorporated herein by reference).
10.8	Form of Promissory Note Extension Agreements due September 30, 2011 with an interest rate of 5% between the Company and two director consultants dated June 30, 2011 for an aggregate principal amount of $243,175 (previously filed as Exhibit 10.2 to our Current Report on Form 8-K filed on July 7, 2011 and incorporated herein by reference).

10.9	Standard Sublease executed August 1, 2011, and dated for reference purposes only July 28, 2011 (previously filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 4, 2011 and incorporated herein by reference).
10.10	Promissory Note delivered to Vanahab Health Diagnostics, LLC dated August 15, 2011 (previously filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 19, 2011 and incorporated herein by reference).
10.11	Software License Agreement between Robertson Technologies Licensing, LLC and Sanlam Health effective September 12, 2011 (previously filed as Exhibit 10.1 to our Current Report on Form 8-K filed on September 14, 2011 and incorporated herein by reference).
10.12	Promissory Note delivered to Vanahab Health Diagnostics, LLC dated September 9, 2011 (previously filed as Exhibit 10.2 to our Current Report on Form 8-K filed on September 14, 2011 and incorporated herein by reference).
10.13	Software License Agreement between Robertson Technologies Licensing, LLC and Telemedicine Africa (Pty) Ltd effective September 29, 2011 (previously filed as Exhibit 10.1 to our Current Report on Form 8-K filed on October 3, 2011 and incorporated herein by reference).
10.14	Form of Promissory Note Extension Agreements due December 31, 2011 with interest rates of 10% to 18% between the Company and three creditors dated September 29, 2011 for an aggregate principal amount of $237,500 (previously filed as Exhibit 10.2 to our Current Report on Form 8-K filed on October 3, 2011 and incorporated herein by reference).
10.15	Form of Promissory Note Extension Agreements due December 31, 2011 with an interest rate of 5% between the Company and two director consultants dated September 29, 2011 for an aggregate principal amount of $243,175 (previously filed as Exhibit 10.3 to our Current Report on Form 8-K filed on October 3, 2011 and incorporated herein by reference).
21.1	Subsidiaries (previously filed as Exhibit 21.1 to our Quarterly Report on Form 10-Q filed on August 16, 2010 and incorporated herein by reference).
23.1*	Consent of Silberstein Ungar, PLLC.
31.1*	Certification of Joel C. Robertson pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
31.2*	Certification of Melissa A. Seeger pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
32.1*	Certifications pursuant to 18 U.S.C. Section 1350.
101.INS**	XBRL Instance.
101.SCH**	XBRL Taxonomy Extension Schema.
101.CAL**	XBRL Taxonomy Extension Calculation.
101.DEF**	XBRL Taxonomy Extension Definition.
101.LAB**	XBRL Taxonomy Extension Labels.
101.PRE**	XBRL Taxonomy Extension Presentation.

	Robertson Global Health Solutions Corporation

	By:	/s/ Joel C. Robertson
		Chairman, President and Chief Executive Officer

Name	Position		Date


/s/ Joel C. Robertson		Chairman, President and	December 29, 2011
Joel C. Robertson		Chief Executive Officer
		(Principal Executive Officer)


/s/ Melissa A. Seeger		Chief Financial Officer,	December 29, 2011
Melissa A. Seeger		Treasurer and Secretary
		(Principal Financial and Accounting Officer)

/s/ Gerald L. Ehrens		Director	December 29, 2011
Gerald L. Ehrens

/s/ Peter J. Perkinson		Director	December 29, 2011
Peter J. Perkinson